Triptorelin embonate 22.5 mg
Sponsors
Debiopharm International SA, Ipsen
Conditions
Prostate Cancer
Phase 3
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
CompletedNCT01656161
Start: 2012-07-31End: 2013-08-31Updated: 2015-09-15
Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate
CompletedNCT05458856
Start: 2022-08-30End: 2024-07-08Updated: 2025-07-25